| 📌 The essentials On March 18, 2026, the FDA approved ICOTYDE (icotrokinra, Johnson & Johnson) for the treatment of moderate to severe plaque psoriasis in adults and adolescents aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. What makes it mechanistically distinctive: icotrokinra is the first oral peptide that directly blocks the IL-23 receptor, not the IL-23 ligand. All currently approved IL-23-targeting biologics (guselkumab, risankizumab, tildrakizumab) are monoclonal antibodies targeting the IL-23 cytokine itself. Icotrokinra works at the receptor level, introducing a distinct pharmacological approach in an established mechanism. How it is taken: one 200 mg tablet once daily, taken with water upon waking, at least 30 minutes before eating. May be dispersed in water for patients who have difficulty swallowing tablets. Who it is approved for: adults and adolescents aged 12 and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. The clinical basis: the Phase 3 ICONIC clinical development program across five randomized controlled trials enrolling more than 2,500 patients. Key efficacy numbers at week 16 across trials: IGA 0/1 (clear or almost clear skin) approximately 65 to 70%; PASI 90 approximately 50 to 57%. In head-to-head comparisons, icotrokinra showed superiority to deucravacitinib (Sotyktu) on both primary endpoints. At 52 weeks, complete skin clearance (PASI 100) rates increased to 48 to 49% in two pivotal studies. |
|---|
Plaque psoriasis is among the most common immune-mediated skin conditions in the world, affecting more than 125 million people globally. It is not primarily a cosmetic problem. The chronic inflammation that drives the characteristic plaques, scaling, and itch also carries systemic consequences: psoriatic arthritis develops in up to 30% of patients, and individuals with moderate to severe disease have elevated cardiovascular risk, increased rates of depression and anxiety, and substantially reduced quality of life.
The treatment landscape for moderate to severe plaque psoriasis transformed with the arrival of biologics targeting the IL-17 and IL-23 pathways in the 2010s and 2020s. These injectable therapies produce very high rates of skin clearance but require subcutaneous or intravenous administration, carrying an injection burden that affects adherence for some patients. The oral options in this space have been limited: apremilast (Otezla) is a PDE4 inhibitor with more modest efficacy than IL-17 or IL-23 biologics, and deucravacitinib (Sotyktu) targets TYK2 and has shown meaningful but not biologic-comparable clearance rates.
ICOTYDE (icotrokinra), approved March 18, 2026, enters this landscape as the first oral therapy targeting the IL-23 receptor directly. The efficacy data from the ICONIC program puts it in a different category from prior oral options and, on some measures, in range of biologic-level responses, in a once-daily pill.
What Icotrokinra Is and How It Works
IL-23 (interleukin-23) is a cytokine that plays a central role in the inflammatory cascade driving plaque psoriasis. It activates and sustains Th17 cells, the immune cell population that produces IL-17, the downstream cytokine directly responsible for much of the skin inflammation in psoriasis. Blocking IL-23 at any point in this pathway reduces Th17 activation and downstream inflammation.
Existing IL-23-targeting biologics work by binding to the p19 subunit of the IL-23 cytokine itself, preventing it from activating its receptor. Icotrokinra takes a different approach: it is an oral peptide that binds directly to the IL-23 receptor (IL-23R) on the surface of immune cells, blocking the receptor from receiving the IL-23 signal regardless of how much IL-23 is present. This is mechanistically analogous to blocking the lock rather than confiscating the key.
The ability to deliver this level of receptor-targeted precision in an oral small molecule format is what makes icotrokinra mechanistically distinctive. It is not a large protein antibody requiring injection. It is a peptide that survives oral ingestion and reaches the target receptor after absorption from the gastrointestinal tract. The pharmacological challenge of engineering peptides that can do this reliably is substantial, which is why icotrokinra is the first of its kind to reach approval.
| How icotrokinra compares to other oral psoriasis treatments Apremilast (Otezla) is an oral PDE4 inhibitor that broadly dampens inflammatory signaling. It produces IGA 0/1 rates of approximately 20 to 30% at 16 weeks and PASI 75 rates of approximately 40% in pivotal trials. It is generally considered a step below biologics in efficacy for moderate to severe disease. Deucravacitinib (Sotyktu) is an oral TYK2 inhibitor that selectively suppresses IL-23 and IL-12 signaling. In its pivotal POETYK PSO-1 and PSO-2 trials, it produced IGA 0/1 rates of 53 to 58% and PASI 75 rates of 58 to 65% at week 24, positioning it meaningfully above apremilast. Icotrokinra produced IGA 0/1 rates of 65 to 70% and PASI 90 rates of 50 to 57% at week 16 across its pivotal trials, with head-to-head superiority demonstrated directly against deucravacitinib in ICONIC-ADVANCE 1 and 2. No head-to-head trial comparing icotrokinra to IL-17 or IL-23 biologics has been completed. Where icotrokinra fits in the treatment hierarchy will be determined by payer formularies, prescriber experience, and individual patient considerations including injection hesitancy, comorbidities, and treatment history. |
|---|
The ICONIC Clinical Development Program: What the Data Shows
The FDA approval is based on five Phase 3 randomized controlled trials collectively enrolling more than 2,500 patients, designated the ICONIC program. The co-primary endpoints across studies were the proportion of patients achieving IGA 0/1 (clear or almost clear skin) with at least a 2-grade improvement, and PASI 90 (at least 90% improvement in psoriasis severity from baseline), both at week 16.
ICONIC-ADVANCE 1 and 2: the pivotal approval studies with active comparator
The two pivotal trials supporting the approval are ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604), published simultaneously in The Lancet in September 2025. These trials were randomized, double-blind, placebo-controlled and active-comparator-controlled, comparing icotrokinra (200 mg once daily) to both placebo and deucravacitinib (6 mg once daily) in adults with moderate to severe plaque psoriasis.
| Endpoint at Week 16 | Icotrokinra | Placebo | Deucravacitinib |
|---|---|---|---|
| IGA 0/1 (ADVANCE 1) | 68% (213/311) | 11% (17/156) | 49% |
| IGA 0/1 (ADVANCE 2) | 70% (227/322) | 9% (7/82) | 49% |
| PASI 90 (ADVANCE 1) | 55% (171/311) | 4% (6/156) | 36% |
| PASI 90 (ADVANCE 2) | 57% (184/322) | 1% (1/82) | 38% |
| PASI 100 complete clearance (ADVANCE 1, Week 16) | ~33% | Less than 1% | ~17% |
| PASI 100 complete clearance (ADVANCE 2, Week 16) | ~33% | Less than 1% | ~16% |
Source: Gold et al. The Lancet. 2025. doi:10.1016/S0140-6736(25)01576-4.
Both coprimary endpoints and all key secondary endpoints were met in each study. Icotrokinra demonstrated statistically significant superiority over deucravacitinib on both IGA 0/1 and PASI 90 at week 16, with treatment differences of approximately 19 to 20 percentage points on IGA 0/1 and approximately 18 to 19 percentage points on PASI 90 versus deucravacitinib. This head-to-head superiority over the most recently approved oral systemic therapy is the most clinically significant efficacy finding in the dataset.
ICONIC-LEAD: adolescent and adult data
ICONIC-LEAD (NCT06095115) enrolled 684 participants (456 icotrokinra, 228 placebo) in a 2:1 randomization. This study evaluated both adults and adolescents and provides the specific data supporting the pediatric indication. At week 16, 65% of icotrokinra-treated patients achieved IGA 0/1 versus 8% with placebo (difference 56%; 95% CI 50 to 62%), and 50% achieved PASI 90 versus 4% with placebo (difference 45%; 95% CI 40 to 50%). By week 24, these rates improved to 74% IGA 0/1 and 65% PASI 90.
ICONIC-TOTAL: high-impact sites
ICONIC-TOTAL (NCT06095102) specifically enrolled patients with plaque psoriasis affecting high-impact and difficult-to-treat areas including scalp, genitals, and hands/feet. At 52 weeks, 72% of patients with scalp psoriasis achieved scalp-specific IGA 0/1 clearance. Genital and hand/foot clearance rates were similarly high. These difficult-to-treat locations are often where patients report the greatest impact on quality of life and where many existing systemic therapies show lower effectiveness than in non-special site disease.
52-week durability data
One-year data from ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and ICONIC-LEAD, presented at the 2026 American Academy of Dermatology Annual Meeting in March 2026, showed that response rates continued to improve beyond week 16. PASI 100 (completely clear skin) rates increased from 33 to 41% at week 24 to 48 to 49% at week 52 across the two ADVANCE studies. No new safety signals were identified through 52 weeks of treatment.
Safety Profile
Across the ICONIC clinical program, icotrokinra demonstrated what the FDA and independent reviewers characterized as a placebo-like safety profile at week 16, with adverse event rates within 1.1 percentage points of placebo. No new safety signals emerged through 52 weeks of follow-up.
Common adverse events reported in trials:
- Headache
- Nausea
- Cough
- Mild fungal infections (predominantly oral candidiasis)
- Upper respiratory tract infection
- Fatigue
Key safety considerations from the prescribing information:
Tuberculosis screening is required before initiating icotrokinra, consistent with other immunomodulating therapies. Live vaccines should not be administered during treatment. Providers should monitor for signs and symptoms of infection throughout the treatment course.
The absence of the elevated cardiovascular risk signals observed with some JAK inhibitors, and the absence of the hepatic or hematologic monitoring requirements associated with older systemic therapies like methotrexate, are practical clinical advantages in a patient population that often has cardiovascular comorbidities.
Dosing and Administration
- Dose: 200 mg once daily
- Timing: Upon waking, at least 30 minutes before eating
- Method: One tablet swallowed with water. For patients who have difficulty swallowing tablets, the tablet may be dispersed in at least 120 mL of water; administration should be completed within 15 minutes of dispersion
- Who is eligible: Adults and adolescents aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy
Where Icotrokinra Fits in Psoriasis Treatment
Current treatment guidelines from the American Academy of Dermatology recommend a stepwise approach. Topical therapies are typically first-line for mild disease. Systemic therapy becomes appropriate when topical treatments fail or disease is classified as moderate to severe.
For systemic therapy, the options now include:
- Conventional systemic agents: methotrexate, cyclosporine, acitretin. Effective but carry significant monitoring burdens and toxicity profiles
- Apremilast (Otezla): oral PDE4 inhibitor. Modest efficacy, generally better tolerated than conventional systemic agents
- Deucravacitinib (Sotyktu): oral TYK2 inhibitor. More effective than apremilast, now demonstrated to be less effective than icotrokinra on primary endpoints
- Biologic therapies targeting IL-17 or IL-23: highest efficacy class but require injection (ixekizumab, secukinumab, guselkumab, risankizumab, bimekizumab, others)
- Icotrokinra (ICOTYDE): oral IL-23R peptide. Efficacy on primary endpoints exceeds prior oral options and approaches biologic-level response rates in some analyses
Icotrokinra’s approval creates a new clinical decision point for prescribers who have patients with moderate to severe disease who prefer or require oral treatment but have not achieved adequate responses on apremilast or deucravacitinib, or who want to avoid injectable biologics.
Whether icotrokinra will move earlier in the treatment sequence, potentially as first-line systemic therapy, will depend on payer formulary decisions, prescriber adoption patterns, and the results of the ongoing ICONIC-ASCEND trial (NCT06934226), which compares icotrokinra to ustekinumab (an IL-12/23 biologic) and will provide the first direct head-to-head data versus an injectable biologic.
For Patients
If you have moderate to severe plaque psoriasis and are currently on a systemic therapy that is not achieving adequate control, or if you have been reluctant to try injectable biologics, icotrokinra adds a clinically meaningful new oral option to the conversation you can have with your dermatologist.
It is not a replacement for injectable biologics in patients who are doing well on those regimens. It is an alternative for patients for whom oral treatment is preferable, for whom prior oral therapies were insufficient, or who are appropriate candidates for first-line systemic therapy.
Patient support is available through Johnson & Johnson’s ICOTYDE withMe program, which provides cost assistance options and educational resources. Information on eligibility and enrollment is available at icotyde.com.
The National Psoriasis Foundation maintains current information on all approved psoriasis treatments, including patient perspectives, treatment decision support tools, and a healthcare provider directory for finding dermatologists with psoriasis expertise. The American Academy of Dermatology’s “Find a Dermatologist” tool is a reliable starting point for patients seeking specialist care.
For related coverage of first-in-class oral therapies across different conditions in 2026, see our post on Foundayo (orforglipron), the first non-peptide oral GLP-1 receptor agonist approved for weight management, which represents a parallel story of oral formulation innovation changing a treatment landscape previously dominated by injectables.
Sources
FDA approval announcement: FDA approves icotrokinra for moderate to severe plaque psoriasis. FDA.gov. March 18, 2026.
Johnson & Johnson approval press release: FDA Approval of ICOTYDE (icotrokinra) Ushers in New Era for First-Line Systemic Treatment of Plaque Psoriasis. jnj.com. March 18, 2026.
ICONIC-ADVANCE 1 and 2 primary publication: Gold LS, Armstrong A, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. The Lancet. 2025. doi:10.1016/S0140-6736(25)01576-4.
ICONIC-LEAD 24-week data: Phase 3 Findings Suggest Icotrokinra Effective in Adults, Adolescents with Psoriasis. HCPLive. January 2026.
52-week data press release: ICOTYDE (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile. PRNewswire. March 28, 2026.
ICONIC-TOTAL scalp/genital data: Icotrokinra long-term results affirm promise in difficult-to-treat scalp and genital psoriasis. JNJ Investor. October 2025.
Dermatology Times approval coverage: FDA Approves Icotrokinra, First Oral IL-23 Receptor Blocker for Psoriasis. Dermatology Times. April 2026.
HMP Global approval summary: FDA Approves Icotyde for Moderate-to-Severe Plaque Psoriasis. HMP Global Learning Network. March 2026.
Rheumatology Advisor ICONIC-LEAD data: FDA Approves Oral Icotrokinra for Moderate to Severe Plaque Psoriasis. Rheumatology Advisor. March 2026.
ICONIC trial registrations: ICONIC-ADVANCE 1 (NCT06143878) | ICONIC-ADVANCE 2 (NCT06220604) | ICONIC-LEAD (NCT06095115) | ICONIC-TOTAL (NCT06095102)
Deucravacitinib FDA approval: FDA approves deucravacitinib for plaque psoriasis. FDA.gov.
Apremilast FDA approval: FDA approves apremilast for psoriatic arthritis. FDA.gov.
IL-23 pathway reference: IL-23 and psoriasis pathogenesis. PMC6429360.
Biologic therapy review: IL-17 and IL-23 pathway inhibition in psoriasis. PMC7460559.
Patient resources: National Psoriasis Foundation | AAD Find a Dermatologist | ICOTYDE patient support
| Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about psoriasis treatment, including whether icotrokinra is appropriate for your situation, should be made in consultation with a board-certified dermatologist who can evaluate your individual disease characteristics, treatment history, and comorbidities. |
|---|